Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

Press Release - Dr. Feldmann Sir Marc Feldmann to Chair Gradalis Scientific Advisory Board
Press Release First Patient Dosed in Pilot Study of Vigil EATC + Durvalumab in TNBC
Press Release Gradalis, Inc. Appoints Martin J. Birkhofer, M.D. Chief Medical Officer
Press Release Gradalis, Inc. Appoints Sunil Joshi Chief Executive Officer
Vigil®
Immunotherapies
Goal